EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor

CHEBI:CHEBI_77108

Definition

An EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of 15-hydroxyprostaglandin dehydrogenase (NAD(+)) (EC 1.1.1.141).

Alternative Names

  • (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate:NAD(+) 15-oxidoreductase inhibitor
  • (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprost-5,13-dienoate:NAD(+) 15-oxidoreductase inhibitors
  • (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD(+) 15-oxidoreductase inhibitor
  • (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD(+) 15-oxidoreductase inhibitors
  • 11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD(+) 15-oxidoreductase inhibitor
  • 11alpha,15-dihydroxy-9-oxoprost-13-enoate:NAD(+) 15-oxidoreductase inhibitors
  • 15-hydroxyprostaglandin dehydrogenase (NAD(+)) (EC 1.1.1.141) inhibitor
  • 15-hydroxyprostaglandin dehydrogenase (NAD(+)) (EC 1.1.1.141) inhibitors
  • 15-hydroxyprostaglandin dehydrogenase (NAD(+)) inhibitor
  • 15-hydroxyprostaglandin dehydrogenase (NAD(+)) inhibitors
  • 15-hydroxyprostaglandin dehydrogenase inhibitor
  • 15-hydroxyprostaglandin dehydrogenase inhibitors
  • 15-hydroxyprostanoic dehydrogenase inhibitor
  • 15-hydroxyprostanoic dehydrogenase inhibitors
  • 15-OH-PGDH inhibitor
  • 15-OH-PGDH inhibitors
  • EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitors
  • EC 1.1.1.141 inhibitor
  • EC 1.1.1.141 inhibitors
  • NAD-specific 15-hydroxyprostaglandin dehydrogenase inhibitor
  • NAD-specific 15-hydroxyprostaglandin dehydrogenase inhibitors
  • NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (type I) inhibitor
  • NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (type I) inhibitors
  • PGDH inhibitor
  • PGDH inhibitors
  • prostaglandin dehydrogenase inhibitor
  • prostaglandin dehydrogenase inhibitors

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

core#notation
CHEBI:77108
oboInOwl#hasDbXref
Wikipedia:15-hydroxyprostaglandin_dehydrogenase_(NAD%2B)

Additional References

Wikipedia:15-hydroxyprostaglandin_dehydrogenase_(NAD%2B)

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

RO_0000087
http://purl.obolibrary.org/obo/CHEBI_16118
owl#someValuesFrom
t122405
owl#annotatedSource
t293852
oboInOwl#hasOBONamespace
chebi_ontology
oboInOwl#id
CHEBI:77108
core#notation
CHEBI:77108
oboInOwl#hasDbXref
Wikipedia:15-hydroxyprostaglandin_dehydrogenase_(NAD%2B)
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class